A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

Tanios Bekaii-Saab, Julie M. Roda, Kristan D. Guenterberg, Bhuvanaswari Ramaswamy, Donn C. Young, Amy K. Ferketich, Tammy A. Lamb, Michael R. Grever, Charles L. Shapiro, William E. Carson

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Our preclinical work showed a dramatic synergy between interleukin-12 (IL-12) and trastuzumab for stimulation of natural killer cell cytokine secretion. We aimed to determine the safety profile of IL-12 when given in combination with trastuzumab and paclitaxel to patients with metastatic HER2-overexpressing cancers. Paclitaxel was given i.v. at 175 mg/m2 every 3 weeks. Trastuzumab was given on day 1 each week (4 mg/kg initially and 2 mg/kg thereafter) in combination with injections of IL-12 on days 2 and 5 starting in cycle 2. This trial accrued 21 patients with metastatic HER2-positive tumors (breast, 7; colon, 6; esophagus, 4; stomach, 2; pancreas, 1; thyroid, 1). The IL-12 component was dose-escalated in cohorts of three patients. The dose-limiting toxicity was grade 3 fatigue at the 300 ng/kg dose level in two patients. The recommended phase II dose was 200 ng/kg administered s.c. There was one complete response in a patient with breast cancer, partial responses in 4 patients (breast, 2; esophageal, 2), and stabilization of disease lasting 3 months or greater (SD) in 6 other patients. All but one response occurred in patients with HER2 3+ disease. Two SD patients completed 1 year of therapy. Ten patients had progressive disease. There was increased activation of extracellular signal-regulated kinase in peripheral blood mononuclear cells and increased levels of IFN-γ and several chemokines in patients with clinical benefit (complete response, partial response, or SD), but not in patients with progressive disease. IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers.

Original languageEnglish (US)
Pages (from-to)2983-2991
Number of pages9
JournalMolecular Cancer Therapeutics
Volume8
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Interleukin-12
Paclitaxel
Neoplasms
Trastuzumab
Breast Neoplasms
Extracellular Signal-Regulated MAP Kinases
Chemokines
Natural Killer Cells
Esophagus
Fatigue
Pancreas
Blood Cells
Stomach
Thyroid Gland
Colon
Breast
Cytokines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. / Bekaii-Saab, Tanios; Roda, Julie M.; Guenterberg, Kristan D.; Ramaswamy, Bhuvanaswari; Young, Donn C.; Ferketich, Amy K.; Lamb, Tammy A.; Grever, Michael R.; Shapiro, Charles L.; Carson, William E.

In: Molecular Cancer Therapeutics, Vol. 8, No. 11, 01.11.2009, p. 2983-2991.

Research output: Contribution to journalArticle

Bekaii-Saab, T, Roda, JM, Guenterberg, KD, Ramaswamy, B, Young, DC, Ferketich, AK, Lamb, TA, Grever, MR, Shapiro, CL & Carson, WE 2009, 'A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies', Molecular Cancer Therapeutics, vol. 8, no. 11, pp. 2983-2991. https://doi.org/10.1158/1535-7163.MCT-09-0820
Bekaii-Saab, Tanios ; Roda, Julie M. ; Guenterberg, Kristan D. ; Ramaswamy, Bhuvanaswari ; Young, Donn C. ; Ferketich, Amy K. ; Lamb, Tammy A. ; Grever, Michael R. ; Shapiro, Charles L. ; Carson, William E. / A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 11. pp. 2983-2991.
@article{4ddd284ba4c649bcbb0809ab78752dc3,
title = "A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies",
abstract = "Our preclinical work showed a dramatic synergy between interleukin-12 (IL-12) and trastuzumab for stimulation of natural killer cell cytokine secretion. We aimed to determine the safety profile of IL-12 when given in combination with trastuzumab and paclitaxel to patients with metastatic HER2-overexpressing cancers. Paclitaxel was given i.v. at 175 mg/m2 every 3 weeks. Trastuzumab was given on day 1 each week (4 mg/kg initially and 2 mg/kg thereafter) in combination with injections of IL-12 on days 2 and 5 starting in cycle 2. This trial accrued 21 patients with metastatic HER2-positive tumors (breast, 7; colon, 6; esophagus, 4; stomach, 2; pancreas, 1; thyroid, 1). The IL-12 component was dose-escalated in cohorts of three patients. The dose-limiting toxicity was grade 3 fatigue at the 300 ng/kg dose level in two patients. The recommended phase II dose was 200 ng/kg administered s.c. There was one complete response in a patient with breast cancer, partial responses in 4 patients (breast, 2; esophageal, 2), and stabilization of disease lasting 3 months or greater (SD) in 6 other patients. All but one response occurred in patients with HER2 3+ disease. Two SD patients completed 1 year of therapy. Ten patients had progressive disease. There was increased activation of extracellular signal-regulated kinase in peripheral blood mononuclear cells and increased levels of IFN-γ and several chemokines in patients with clinical benefit (complete response, partial response, or SD), but not in patients with progressive disease. IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers.",
author = "Tanios Bekaii-Saab and Roda, {Julie M.} and Guenterberg, {Kristan D.} and Bhuvanaswari Ramaswamy and Young, {Donn C.} and Ferketich, {Amy K.} and Lamb, {Tammy A.} and Grever, {Michael R.} and Shapiro, {Charles L.} and Carson, {William E.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0820",
language = "English (US)",
volume = "8",
pages = "2983--2991",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

AU - Bekaii-Saab, Tanios

AU - Roda, Julie M.

AU - Guenterberg, Kristan D.

AU - Ramaswamy, Bhuvanaswari

AU - Young, Donn C.

AU - Ferketich, Amy K.

AU - Lamb, Tammy A.

AU - Grever, Michael R.

AU - Shapiro, Charles L.

AU - Carson, William E.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Our preclinical work showed a dramatic synergy between interleukin-12 (IL-12) and trastuzumab for stimulation of natural killer cell cytokine secretion. We aimed to determine the safety profile of IL-12 when given in combination with trastuzumab and paclitaxel to patients with metastatic HER2-overexpressing cancers. Paclitaxel was given i.v. at 175 mg/m2 every 3 weeks. Trastuzumab was given on day 1 each week (4 mg/kg initially and 2 mg/kg thereafter) in combination with injections of IL-12 on days 2 and 5 starting in cycle 2. This trial accrued 21 patients with metastatic HER2-positive tumors (breast, 7; colon, 6; esophagus, 4; stomach, 2; pancreas, 1; thyroid, 1). The IL-12 component was dose-escalated in cohorts of three patients. The dose-limiting toxicity was grade 3 fatigue at the 300 ng/kg dose level in two patients. The recommended phase II dose was 200 ng/kg administered s.c. There was one complete response in a patient with breast cancer, partial responses in 4 patients (breast, 2; esophageal, 2), and stabilization of disease lasting 3 months or greater (SD) in 6 other patients. All but one response occurred in patients with HER2 3+ disease. Two SD patients completed 1 year of therapy. Ten patients had progressive disease. There was increased activation of extracellular signal-regulated kinase in peripheral blood mononuclear cells and increased levels of IFN-γ and several chemokines in patients with clinical benefit (complete response, partial response, or SD), but not in patients with progressive disease. IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers.

AB - Our preclinical work showed a dramatic synergy between interleukin-12 (IL-12) and trastuzumab for stimulation of natural killer cell cytokine secretion. We aimed to determine the safety profile of IL-12 when given in combination with trastuzumab and paclitaxel to patients with metastatic HER2-overexpressing cancers. Paclitaxel was given i.v. at 175 mg/m2 every 3 weeks. Trastuzumab was given on day 1 each week (4 mg/kg initially and 2 mg/kg thereafter) in combination with injections of IL-12 on days 2 and 5 starting in cycle 2. This trial accrued 21 patients with metastatic HER2-positive tumors (breast, 7; colon, 6; esophagus, 4; stomach, 2; pancreas, 1; thyroid, 1). The IL-12 component was dose-escalated in cohorts of three patients. The dose-limiting toxicity was grade 3 fatigue at the 300 ng/kg dose level in two patients. The recommended phase II dose was 200 ng/kg administered s.c. There was one complete response in a patient with breast cancer, partial responses in 4 patients (breast, 2; esophageal, 2), and stabilization of disease lasting 3 months or greater (SD) in 6 other patients. All but one response occurred in patients with HER2 3+ disease. Two SD patients completed 1 year of therapy. Ten patients had progressive disease. There was increased activation of extracellular signal-regulated kinase in peripheral blood mononuclear cells and increased levels of IFN-γ and several chemokines in patients with clinical benefit (complete response, partial response, or SD), but not in patients with progressive disease. IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers.

UR - http://www.scopus.com/inward/record.url?scp=70949093473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70949093473&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0820

DO - 10.1158/1535-7163.MCT-09-0820

M3 - Article

VL - 8

SP - 2983

EP - 2991

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -